News
PSTV
1.660
+1.84%
0.030
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics selected for $3 million in funding recommendation by the Department of Defense. The company has $23 million in active awards support for its targeted radiotherapeutic pipeline. The award will support the expansion of the company's clinical trial for pediatric brain cancer.
Benzinga · 1d ago
Press Release: Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Plus Therapeutics Receives $3 million Award Recommendation from the United States Department of Defense Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline. Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract finalization. Plus is a clinical-stage pharmaceutical company developing targeted radiotherapy for central nervous system cancers.
Dow Jones · 1d ago
Weekly Report: what happened at PSTV last week (0415-0419)?
Weekly Report · 1d ago
Plus Therapeutics Inc <PSTV.OQ> expected to post a loss of $1.09 a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of $1.09 a share. The company is expected to report a 233.5% increase in quarterly revenue. Plus Therapeutic Inc PSTV. OQ is scheduled to report results on April 18 for the period ending March 31 2024.
Reuters · 6d ago
Weekly Report: what happened at PSTV last week (0408-0412)?
Weekly Report · 04/15 09:51
Weekly Report: what happened at PSTV last week (0401-0405)?
Weekly Report · 04/08 09:53
Weekly Report: what happened at PSTV last week (0325-0329)?
Weekly Report · 04/01 09:53
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/27 21:10
Weekly Report: what happened at PSTV last week (0318-0322)?
Weekly Report · 03/25 09:54
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Plus Therapeutics (PSTV) was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target for the company. The company's lead asset, rhenium obisbemeda, has shown promising results in clinical trials.
TipRanks · 03/22 16:45
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) and Plus Therapeutics (PSTV) have been upgraded to Buy by 2 analysts today. The company's shares closed at $1.65 on Friday. The analysts are bullish on the Healthcare sector and the company's prospects. Plus TherAPEutics and Milestone PharmaceuticalS have a combined market value of $1 billion.
TipRanks · 03/22 16:40
Weekly Report: what happened at PSTV last week (0311-0315)?
Weekly Report · 03/18 09:53
Plus Therapeutics CEO’s Insightful Presentation Now Available
TipRanks · 03/13 12:12
Weekly Report: what happened at PSTV last week (0304-0308)?
Weekly Report · 03/11 09:52
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
TipRanks · 03/07 15:35
Plus Therapeutics Is Worried About This – Should You Be Worried Too?
TipRanks · 03/07 06:01
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
Plus Therapeutics reported earnings per share of -70 cents. The company reported revenue of $1.31 million. This was 23.87% better than the analyst estimate for revenue of -$1.06 million. Plus Therapeutic is a subsidiary of AstraZeneca.
Investorplace · 03/06 02:52
Plus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Plus Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 84 cents per share. Revenue rose 769.5% to $1.31 million from a year ago. Plus Therapeutic Inc shares had risen by 21.7% this quarter.
Reuters · 03/05 23:43
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/05 22:35
Recap: Plus Therapeutics Q4 Earnings
Plus Therapeutics reported its Q4 earnings of $-0.7. The company beat estimates by 35.0%. The company's revenue was up $1.16 million from the same period last year. Last quarter the company beat on EPS by $0.12.
Benzinga · 03/05 21:35
More
Webull provides a variety of real-time PSTV stock news. You can receive the latest news about Plus Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.